Austria has one of the strongest non-dilutive MedTech funding ecosystems in Europe. The three national levers are FFG (the research promotion agency), AWS (the promotional bank), and BASIS-style innovation programs that have historically supported qualifying MedTech products at meaningful scale — in some cases up to around EUR 1 million. Regional accelerators in Upper Austria, Graz, and Vienna add a second layer, and the free Austrian healthcare system creates a market-entry advantage that founders in insurance-based systems underestimate. Before relying on any specific program figure in a business plan, verify the current terms directly with the administering agency — windows, eligibility, and co-financing ratios move from year to year.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • Austria's MedTech funding stack has three national levers — FFG, AWS, and BASIS-style innovation programs — plus regional accelerators and university spinoff pathways that most first-time founders never fully explore.
  • Historical program ceilings for qualifying MedTech products have reached up to around EUR 1 million in certain BASIS-style windows. These figures are historical reference points, not current guarantees. Verify live program terms with the administering agency before putting any number into a plan.
  • The free Austrian healthcare system is a structural market-entry advantage for MedTech products that fit public provision — reimbursement conversations are different when the payer is a single public system rather than a fragmented insurance market.
  • Upper Austria (including the AplusB incubator network and the local MedUni environment), Graz (MedUni Graz and the surrounding cluster), and Vienna (the largest concentration of life-science VCs and accelerators) each offer distinct regional advantages.
  • The right sequence for most Austrian MedTech founders is non-dilutive first, then angel, then institutional seed — skipping the non-dilutive layer usually costs more equity than it saves time.
  • Every euro raised in Austria is still subject to the same MDR obligations as any other EU MedTech project. Regulation (EU) 2017/745, Article 10, applies equally whether the funding came from Vienna, Berlin, or Boston.

Why Austria is a useful case study for MedTech funding

If you had to pick one small European country to locate an early-stage MedTech startup, Austria would be on the shortlist — and not for sentimental reasons. The ecosystem is dense, the programs are well-defined, the administering agencies are accessible, and the public healthcare system removes a layer of commercial friction that founders in larger insurance-based markets have to fight through for years.

This post is a concrete walk-through of how the Austrian MedTech funding landscape works in practice, written from the perspective of founders we have coached and companies Tibor has either founded or advised directly. It is meant as a geography-specific example inside the broader funding category — the parent post, funding a MedTech startup, covers the general principles that apply in any jurisdiction.

The core caveat sits at the top of everything that follows. Austrian funding programs change. Windows open and close, eligibility criteria shift, co-financing ratios move, and new programs replace old ones under new names. Every specific figure in this post is a historical reference point for orientation, not a guarantee. Before you put a number into a funding plan, verify the current terms directly with the administering agency. This is not a disclaimer — it is a working rule.

Overview of the Austrian MedTech ecosystem

Austria is a small country with a high density of MedTech activity relative to its population. The reasons are structural. It has two strong MedUni hospitals with long research traditions (MedUni Vienna and MedUni Graz), a well-developed technical university network producing biomedical engineers, an AplusB incubator programme that has historically channelled university research toward commercial spinoffs, and a public funding system that has genuinely prioritised life sciences for the better part of two decades.

The country also has a single-payer, tax-funded public healthcare system. Every resident is covered. The system is one of the higher-spending systems in Europe in absolute terms, and — crucially for MedTech founders — the procurement and reimbursement conversations happen through public channels rather than dozens of competing private insurers. This does not make market entry easy. Nothing makes MedTech market entry easy. But it does concentrate the decision-makers, which shortens the time you spend mapping stakeholders.

The funding ecosystem has three national layers (FFG, AWS, BASIS-style programmes) and a regional layer that varies by province (Bundesland). The three largest regional ecosystems for MedTech are Upper Austria (Linz and surroundings, with the JKU medical faculty and the AplusB incubator network), Styria (Graz, with MedUni Graz and a strong medtech cluster), and Vienna (the largest life-science investor and accelerator concentration in the country).

AWS — Austria Wirtschaftsservice

AWS is the national promotional bank of Austria. Its role is to provide financing instruments that sit between pure research funding and commercial venture capital — loans, loan guarantees, grants, and equity-style instruments aimed at companies moving from research output toward market entry.

For MedTech startups specifically, AWS has historically operated programmes relevant to three moments in the company's life. The first is the early seed moment, where the company has a prototype and a regulatory plan but is not yet ready for an equity round. The second is the scale-up moment, where the company has achieved early traction and needs growth capital that does not dilute as aggressively as VC. The third is the guarantee moment, where AWS backstops a bank loan the company could not otherwise secure on its own risk profile.

The practical implication for founders is that AWS is worth a conversation before you assume your only options are grants and equity. The instruments are designed to be used. The application process is substantive but not impossible, and the AWS staff are accessible for pre-application discussions. What AWS is willing to fund this year, under what terms, is a live question — check the current programme list directly at aws.at before you design your funding sequence.

FFG — Österreichische Forschungsförderungsgesellschaft

FFG is the Austrian Research Promotion Agency. It is the largest public research funding body in the country and runs a portfolio of programmes that cover basic research, applied research, industrial R&D, and transnational research cooperation.

For a MedTech startup, the FFG programmes worth knowing about typically sit in the applied research and industrial development space. These are competitive, peer-reviewed grants that co-finance project costs (the company contributes a share, usually meaningful) in exchange for grant funding that does not touch the cap table. Historically, FFG has been one of the most important non-dilutive sources for Austrian MedTech companies in the pre-clinical, prototype, and early industrial development phases.

The honest picture of FFG from the founder seat is this. Applications take work. Cycles run in months, not weeks. Reporting requirements continue after the grant is awarded. The evaluation panels are expert panels, and they will ask substantive scientific and commercial questions. First-time applicants usually benefit from a local partner — an incubator, a university transfer office, or a consultant — who has written successful FFG applications before.

The payoff, when it works, is capital that costs no equity. For a capital-intensive MedTech project that has a strong research or innovation component, FFG is often the single most important funding source in the pre-seed and seed stages. Skipping it because the paperwork feels heavy is almost always the wrong call.

BASIS-style innovation programmes — and the "up to EUR 1 million" caveat

There is a class of Austrian innovation programmes — BASIS is the shorthand name most founders in the ecosystem recognise — aimed specifically at high-potential, innovation-driven projects that are moving from research toward a defined market. These programmes have historically supported qualifying MedTech projects at meaningful scale, in some cases up to around EUR 1 million for a single qualifying project.

This figure needs a serious caveat attached to it. The "up to EUR 1 million" number is a historical reference point for certain windows and certain project types, not a standing offer. Programme names change. Windows open and close. Eligibility criteria shift. The amount you could have applied for two years ago may not be the amount you can apply for today, and a programme name that existed last year may have been replaced by a successor programme with different terms.

The working rule for every founder reading this: before you put a specific euro amount from any Austrian innovation programme into a business plan, a pitch deck, or a board document, verify the current terms directly with the administering authority. Ask what is open right now, under what rules, for what project types, at what co-financing ratio. Treat any figure in any blog post — including this one — as historical orientation, not a guarantee.

With that caveat clearly in place: the reason the BASIS-style layer matters is that it is the one part of the Austrian non-dilutive stack where grants can reach an amount meaningful enough to carry a MedTech project through a significant chunk of the MDR pre-revenue window. For the right project, at the right moment, in the right window, it can be the difference between raising a seed round on weak terms and raising it from a position of strength.

Regional accelerators — Upper Austria, Graz, and Vienna

On top of the national layer, Austria has a regional layer that varies by province. For MedTech, three regions stand out.

Upper Austria (Oberösterreich). Linz and the surrounding area have built a strong innovation infrastructure around the JKU and the AplusB incubator network. The AplusB programme is the national academic business accelerator framework, and the Upper Austrian nodes have supported multiple MedTech spinoffs from the local MedUni and technical faculties. The regional development agencies also run their own grant programmes, co-funded with national and EU money. Founders with a university research origin in Upper Austria should have the AplusB pathway on the list before anything else.

Styria (Graz). Graz is Tibor's home base. MedUni Graz is one of the two leading medical universities in the country, and the surrounding ecosystem — Silicon Alps Cluster, the Styrian Human Technology cluster, and a long history of medtech and biotech spinoffs — makes Graz one of the most MedTech-native regional environments in Austria. Regional funding flows through the SFG (the Styrian promotional agency) in coordination with national FFG and AWS instruments.

Vienna. Vienna has the largest absolute concentration of life-science investors, accelerators, and public-sector MedTech programmes in Austria. The Vienna Business Agency runs its own grant and accelerator programmes, the local AplusB nodes operate out of the technical and medical universities, and the angel and early-stage VC density is higher than anywhere else in the country. For founders whose network or co-founder team is Vienna-based, the regional layer is a meaningful addition to the national stack.

The practical implication is that your funding sequence should be shaped by where you are incorporated and physically operating. The regional layer is real money, but it is only accessible if your company qualifies under the specific province's rules.

The free healthcare system as market-entry advantage

One structural feature of the Austrian landscape that most foreign founders underestimate is the public healthcare system. Every resident is covered by tax-funded, largely free-at-point-of-service care. Hospitals are predominantly public or public-equivalent. Reimbursement decisions for medical devices, digital health products, and diagnostic services happen through public channels that — while not simple — are more concentrated than the fragmented insurance markets in countries like Germany or the United States.

For a MedTech product that fits into public provision, this is a meaningful commercial advantage. You are not negotiating with fifty different payers. You are not spending years building separate reimbursement files for competing private insurers. The public pathway is harder to get into than a permissive private pathway in some respects — the scrutiny is real and the timelines are not short — but once you are in, the market access is broader and more durable.

This matters for funding conversations in two ways. First, an Austrian MedTech startup can plausibly raise on the story that the local market entry is a clearer pathway than in a fragmented insurance market, provided the product and the clinical evidence fit public procurement criteria. Second, the same feature that makes the Austrian market attractive — the concentrated payer — is also the feature that makes the market rigid for products that do not fit public provision well. Both sides of that are worth telling investors honestly.

Felix's line from coaching sessions with Austrian founders is worth sitting with. The advantage of a free healthcare system is not that it makes selling easy. It is that it makes the selling conversation structurally different — fewer counter-parties, clearer decision criteria, longer time horizons, and a different kind of evidence burden. Plan for that structure, do not pretend it does not exist, and do not assume it maps to how you would sell in an insurance-based market.

Non-dilutive vs dilutive — the sequencing question

The general principle from the parent funding post applies with extra force in Austria: exhaust the non-dilutive options before giving up equity. The reason the principle is sharper here is that the Austrian non-dilutive stack is genuinely substantive. A qualifying MedTech project with a strong research component can raise several hundred thousand euros, and in the right window more, from FFG, AWS, BASIS-style programmes, and regional instruments — without touching the cap table.

The sequencing that works for most Austrian founders runs roughly like this. First, identify the non-dilutive programmes you plausibly qualify for, and build a calendar of application windows. Second, apply in parallel where the programmes are complementary rather than mutually exclusive. Third, use the first tranches of non-dilutive capital to reach the milestones that will make the eventual equity round raise on better terms — prototype, initial usability, classification rationale, regulatory plan. Fourth, raise the angel or seed round from a position of demonstrated progress rather than pre-milestone weakness.

The alternative sequence — skipping non-dilutive, raising equity first, and using the equity money to cover work that would have been grant-fundable — is common among founders in a hurry. It almost always costs more equity than the time saved is worth.

Common mistakes founders make with Austrian funding

Four patterns repeat across the founders we have seen:

Applying late. Grants run on cycles. Applying to a programme whose next window is six months away does not help the founder who needs money now. Mapping the windows at the start of the year, not the start of the crisis, is the first discipline.

Under-specifying the innovation angle. FFG and BASIS-style panels evaluate innovation seriously. "We are building a medical device" is not an innovation story. Writing the application as if the reviewer understands MedTech obviously — and without explicitly framing what is novel, what is defensible, and what the scientific or technical step-change is — fails every time.

Ignoring the co-financing requirement. Most Austrian grant instruments require the company to co-finance a share of the project. Founders who miss this line end up with an awarded grant they cannot actually draw down because they do not have the matching capital on hand.

Treating regional programmes as irrelevant. The regional layer is not a rounding error. For many projects, the province-level programmes are the single most accessible layer because they are less crowded than the national queue.

The Subtract to Ship angle

The Subtract to Ship framework applied to Austrian funding is not "apply to everything." It is "apply to the programmes whose work produces the milestones you need anyway, and skip the ones whose reporting requirements would drain more time than the grant is worth." Not every grant is a good grant at every stage. A small grant with heavy reporting obligations can be worse than no grant at all when the founder's time is the binding constraint.

The subtraction discipline here is to ask, for every possible application, whether the money plus the ecosystem relationships plus the validation signal are worth the calendar cost of the application and the subsequent reporting. Sometimes the answer is yes and sometimes the answer is no. The honest answer is more often yes than founders think — the Austrian ecosystem is genuinely generous — but the discipline is to answer it deliberately, not reflexively.

Every euro raised through the Austrian non-dilutive stack is still subject to the same MDR obligations under Regulation (EU) 2017/745, Article 10, that apply to any other EU MedTech project. The funding source does not change the regulatory burden. It changes how you finance meeting it.

Reality Check — Where do you stand?

  1. Do you have a current-year calendar of FFG, AWS, and BASIS-style application windows relevant to your project, or are you planning to find out when you need money?
  2. Have you spoken directly to the administering agencies to confirm current programme terms, or are you working from figures in blog posts and pitch decks?
  3. Do you know which regional programmes your province of incorporation makes you eligible for, and have you mapped those alongside the national layer?
  4. Does your financial model include the co-financing share for every grant you are planning to apply for?
  5. If your Austrian non-dilutive applications all failed, would your equity round be raising to fund genuine R&D — or to fund work that should have been grant-fundable?
  6. Does your reimbursement plan take the structure of the Austrian public healthcare system into account, or is it a generic EU-level plan?
  7. If a FFG reviewer asked you to state the scientific or technical innovation in two sentences, could you?

Frequently Asked Questions

What is the best Austrian funding programme for a MedTech startup? There is no single best programme — the right stack depends on the stage, the innovation angle, the province of incorporation, and the co-financing capacity of the company. Most successful Austrian MedTech startups use a combination of FFG grants for research and applied R&D, AWS instruments for the bridge to commercialisation, BASIS-style innovation programmes where they qualify, and regional accelerators where available. Start by mapping what each layer can contribute before picking one.

How much can I actually raise from Austrian non-dilutive sources? Amounts vary widely by programme and window. Historically, qualifying MedTech projects have raised anywhere from tens of thousands of euros in smaller regional instruments to around EUR 1 million in certain BASIS-style windows. These figures are historical reference points — before relying on any specific number, verify current programme terms directly with the administering agency.

Do I need to be Austrian to apply for Austrian funding? In most cases you need an Austrian legal entity, not an Austrian passport. The company must be incorporated in Austria and typically must be doing the work on Austrian soil. Some EU-level instruments allow transnational consortia, which is a different pathway. The specific eligibility rules are programme-by-programme.

Is the Austrian healthcare system really an advantage, or is that marketing? It is structurally different from insurance-based markets and that difference is real. Public provision means a more concentrated decision process and broader access once approved — but it also means longer timelines and harder evidence requirements for some product types. It is an advantage for products that fit, and a constraint for products that do not. The honest answer depends on your device.

Does Austrian funding help with the MDR certification work itself? Indirectly, yes. Several programmes fund R&D work that feeds into the technical file, clinical evaluation, and usability documentation that MDR (Regulation (EU) 2017/745), Article 10, requires manufacturers to assemble. They do not fund the Notified Body fees themselves in most cases. Plan the regulatory budget separately from the grant budget.

How long do Austrian grant applications take? Plan months, not weeks, from intent to cash. FFG cycles, AWS assessments, and BASIS-style windows all run on multi-month timelines, and the reporting after award adds ongoing work. This is why mapping windows at the start of the year matters — a grant that arrives nine months late does not save the company.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 10 (manufacturer obligations). Official Journal L 117, 5.5.2017.
  2. FFG — Österreichische Forschungsförderungsgesellschaft, programme information. https://www.ffg.at — verify current programme terms directly with the agency before relying on specific figures.
  3. AWS — Austria Wirtschaftsservice, programme information. https://www.aws.at — verify current programme terms directly with the agency before relying on specific figures.
  4. BASIS and related Austrian innovation programmes — verify current programme names, windows, and eligibility directly with the administering authority before relying on specific figures.
  5. AplusB — Austrian academic business accelerator network, programme information and regional node listings. Verify current programme terms with the relevant regional operator.

Note on figures: Every euro amount, programme name, and eligibility detail in this post is historical orientation, not a current guarantee. Austrian funding windows change. Before any specific figure from this post enters a business plan, pitch deck, or board document, confirm the current terms directly with the administering agency.

This post is part of the Funding, Business Models & Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. Tibor is based in Graz and has walked multiple Austrian MedTech founders through the non-dilutive stack from first application to first euro of drawdown — when the specific shape of your project and the specific window you are applying into exceeds what a blog post can cover, a conversation with someone who has navigated the Austrian system end-to-end is the shortest path to a clean application.